Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tuvutromstat · IDE-397, GSK-4362676

Small molecule · Inhibitor of methionine adenosyltransferase II alpha (MAT2A) · developed by IDEAYA Biosciences

Phase 1 Most advanced trial
IDYA Developer
1 Registered trials

What is Tuvutromstat?

Tuvutromstat is an orally bioavailable inhibitor of MAT2A, a metabolic enzyme that produces S-adenosyl-L-methionine, the primary methyl donor for cellular transmethylation. It is being studied in solid tumors, particularly MTAP-deleted cancers that depend heavily on SAM synthesis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IDE-397, GSK-4362676
Drug type
Small molecule
Targets
methionine adenosyltransferase II alpha (MAT2A)
Mechanism
Inhibitor of methionine adenosyltransferase II alpha (MAT2A)
Pathways
S-adenosyl-L-methionine synthesis, transmethylation, methionine salvage pathway
Therapy area
Oncology
Developer
IDEAYA Biosciences (IDYA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
T46P23PK39

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04794699 Phase 1 Solid Tumor Active not recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor

Other drugs acting on MAT2A

More from IDEAYA Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.

Follow IDYA, the company behind Tuvutromstat

See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IDYA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.